Liraglutide: Uses, Mechanism, and Side Effects

Anyone considering a GLP-1 medication for weight management likely wants to know what it actually does in the body and what side effects to expect. Liraglutide is one of the earlier approved drugs in this class, with a substantial trial and post-marketing safety record behind it.

Key takeaways

• Liraglutide is a GLP-1 receptor agonist approved to support weight reduction alongside diet and exercise.
• It carries a boxed warning on its label.
• Approved uses cover certain adults and pediatric patients 12 and older with obesity, and adults with overweight plus a weight-related condition.
• More than 550 registered trials have studied liraglutide, including completed phase 3 and phase 4 studies.
• The most commonly reported adverse events involve the gastrointestinal system, led by nausea.

What Liraglutide Is

Liraglutide is a GLP-1 receptor agonist, meaning it mimics a hormone the body naturally produces called GLP-1. It shares 97% of its amino acid sequence with the body's own GLP-1. By binding to and activating the GLP-1 receptor, it triggers a signaling pathway inside cells. This matters because natural GLP-1 breaks down within minutes, while liraglutide is designed to act longer.

What Liraglutide Is Approved For

Liraglutide injection is indicated, along with a reduced calorie diet and increased physical activity, to reduce excess body weight and help maintain that reduction over time. This approval applies to adults and pediatric patients aged 12 and older who weigh more than 60 kg and have obesity, as well as to adults with overweight who also have at least one weight-related comorbid condition. The label notes it should not be combined with other liraglutide-containing products or other GLP-1 receptor agonists. It is marketed under the brand name Liraglutide, and its safety and effectiveness for pediatric type 2 diabetes have not been established. The label carries a boxed warning.

What the Evidence Shows

More than 550 clinical trials have registered liraglutide as a study drug. Among them, a completed phase 3 trial, the RISE Adult Medication Study, examined its use in adults. A completed phase 4 trial looked at weight maintenance and knee imaging in obese patients with knee osteoarthritis, while a phase 4 study on intensive short-term drug therapy in type 2 diabetes has an unknown current status.

Reported Side Effects

Adverse event reports submitted to FAERS are dominated by gastrointestinal symptoms: nausea (7,330 reports), vomiting (3,630), and diarrhoea (3,494). Blood glucose increased was also frequently reported (4,107), along with pancreatitis (2,359), decreased appetite (2,175), weight decreased (2,165), and headache (2,067). These figures reflect the number of reports submitted, not confirmed incidence rates or proof that liraglutide caused the event.